Saptagir Laboratories signs deal with Jubilant Generics to manufacture remdesivir
Hyderabad-based Saptagir Laboratories has entered into an agreement with Jubilant Generics to manufacture intermediates and Active Pharmaceutical Ingredient(API) for intravenous administered drug, remdesivir.
The drug will be produce davits Hyderabad WHO GMP certiļ¬ed sterile drug product manufacturing plant. Mr. Mahesh Reddy, Promoter & Chairman, Saptagir Group said, “Weave had several successes in product development in molecules that were previously only manufactured in China. This partnership meets the need of our multinational customers who approve India as a strong second source for products beyond China. With the new investment of Rs. 75-crores in the pharma plant at Hyderabad we will further grow our presence.